Skip to main content

Table 4 Summary of AEs and their relation to DSG treatment, outcome

From: Treatment of active lupus nephritis with the novel immunosuppressant 15-deoxyspergualin: an open-label dose escalation study

   Number of AE records Number of patients
   n n
Total AE   329 21
Type of AE Infections and infestations 59 18
  Gastrointestinal disorders 52 16
  General disorders/administration site condition 39 17
Intensity Mild 218 21
  Moderate 90 18
  Severe 17 7
Outcome Resolved 221 21
  Additional therapy 81 16
  Hospitalization 14 7
  Premature termination 8 5
Relationship to DSG No 156 20
  Unlikely 42 15
  Possibly 86 18
  Probably 37 13
  Definitely 6 4
  1. AE, adverse event; DSG, deoxyspergualin.